| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
|
Witzig, T.E.
|
|
|
26 |
8 |
p. 1667-1677
|
artikel
|
| 2 |
Adjuvant systemic therapy in breast cancer: quo vadis?
|
Sonnenblick, A.
|
|
|
26 |
8 |
p. 1629-1634
|
artikel
|
| 3 |
An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer
|
Togashi, Y.
|
|
|
26 |
8 |
p. 1800-1801
|
artikel
|
| 4 |
Anthropometric factors and endometrial cancer risk: a systematic review and dose–response meta-analysis of prospective studies
|
Aune, D.
|
|
|
26 |
8 |
p. 1635-1648
|
artikel
|
| 5 |
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
|
Ramalingam, S.
|
|
|
26 |
8 |
p. 1741-1748
|
artikel
|
| 6 |
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
|
Cherny, N.I.
|
|
|
26 |
8 |
p. 1547-1573
|
artikel
|
| 7 |
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
|
Rodon, J.
|
|
|
26 |
8 |
p. 1791-1798
|
artikel
|
| 8 |
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial †
|
Fernandez-Martos, C.
|
|
|
26 |
8 |
p. 1722-1728
|
artikel
|
| 9 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
|
Vansteenkiste, J.
|
|
|
26 |
8 |
p. 1734-1740
|
artikel
|
| 10 |
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
|
Tie, J.
|
|
|
26 |
8 |
p. 1715-1722
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
26 |
8 |
p. ii-iii
|
artikel
|
| 12 |
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
|
Azim Jr, H.A.
|
|
|
26 |
8 |
p. 1521-1523
|
artikel
|
| 13 |
Heterogeneity of driver genes and therapeutic implications in colorectal cancer
|
Dienstmann, R.
|
|
|
26 |
8 |
p. 1523-1525
|
artikel
|
| 14 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
|
Normanno, N.
|
|
|
26 |
8 |
p. 1710-1714
|
artikel
|
| 15 |
High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial
|
Ferreri, A.J.M.
|
|
|
26 |
8 |
p. 1760-1765
|
artikel
|
| 16 |
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets
|
Fallet, V.
|
|
|
26 |
8 |
p. 1748-1753
|
artikel
|
| 17 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
|
Gnant, M.
|
|
|
26 |
8 |
p. 1685-1691
|
artikel
|
| 18 |
IgE and risk of cancer in 37 747 individuals from the general population
|
Helby, J.
|
|
|
26 |
8 |
p. 1784-1790
|
artikel
|
| 19 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma
|
Gakis, G.
|
|
|
26 |
8 |
p. 1754-1759
|
artikel
|
| 20 |
Liquid biopsies to evaluate early therapeutic response in colorectal cancer
|
Montagut, C.
|
|
|
26 |
8 |
p. 1525-1527
|
artikel
|
| 21 |
Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma
|
Meissner, J.
|
|
|
26 |
8 |
p. 1771-1776
|
artikel
|
| 22 |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
|
Gillessen, S.
|
|
|
26 |
8 |
p. 1589-1604
|
artikel
|
| 23 |
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
|
Eberhardt, W.E.E.
|
|
|
26 |
8 |
p. 1573-1588
|
artikel
|
| 24 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
|
Dieci, M.V.
|
|
|
26 |
8 |
p. 1698-1704
|
artikel
|
| 25 |
Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no ‘sweetheart’ solution
|
Tabernero, J.
|
|
|
26 |
8 |
p. 1529-1531
|
artikel
|
| 26 |
Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy
|
Vansteenkiste, J.
|
|
|
26 |
8 |
p. 1527-1529
|
artikel
|
| 27 |
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|
Caplin, M.E.
|
|
|
26 |
8 |
p. 1604-1620
|
artikel
|
| 28 |
Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)
|
Launay-Vacher, V.
|
|
|
26 |
8 |
p. 1677-1684
|
artikel
|
| 29 |
Reply to the letter to the editor ‘ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer’ by Uguen et al.
|
Ilie, M.
|
|
|
26 |
8 |
p. 1802
|
artikel
|
| 30 |
Reply to the letter to the editor ‘Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients’ by Fouad et al.
|
Gnant, M.
|
|
|
26 |
8 |
p. 1799-1800
|
artikel
|
| 31 |
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer
|
Bidard, F.-C.
|
|
|
26 |
8 |
p. 1704-1709
|
artikel
|
| 32 |
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
|
Shi, Y.
|
|
|
26 |
8 |
p. 1766-1771
|
artikel
|
| 33 |
Searching for targets for the systemic therapy of mesothelioma
|
Stahel, R.A.
|
|
|
26 |
8 |
p. 1649-1660
|
artikel
|
| 34 |
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
|
Fizazi, K.
|
|
|
26 |
8 |
p. 1660-1667
|
artikel
|
| 35 |
‘Statistical controversies in clinical research’: a new series in Annals of Oncology
|
Soria, J.-C.
|
|
|
26 |
8 |
p. 1532
|
artikel
|
| 36 |
Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials
|
Thall, P.
|
|
|
26 |
8 |
p. 1621-1628
|
artikel
|
| 37 |
St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists
|
Ignatiadis, M.
|
|
|
26 |
8 |
p. 1519-1520
|
artikel
|
| 38 |
Table of Contents
|
|
|
|
26 |
8 |
p. iv-vi
|
artikel
|
| 39 |
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|
Coates, A.S.
|
|
|
26 |
8 |
p. 1533-1546
|
artikel
|
| 40 |
The first study published?
|
van Oijen, B.P.C.
|
|
|
26 |
8 |
p. 1803
|
artikel
|
| 41 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer
|
Gonçalves, A.
|
|
|
26 |
8 |
p. 1692-1697
|
artikel
|
| 42 |
Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases
|
Stremitzer, S.
|
|
|
26 |
8 |
p. 1728-1733
|
artikel
|
| 43 |
Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium
|
Waterhouse, M.
|
|
|
26 |
8 |
p. 1776-1783
|
artikel
|
Tijdschrift beschrijving